Class II Processing and Presentation During Secondary Responses to Influenza

流感二次反应期间的 II 类处理和呈现

基本信息

  • 批准号:
    8823195
  • 负责人:
  • 金额:
    $ 29.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-12-01 至 2015-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Activation of naive CD4+ T cells (TCD4+) is driven by MHC class II (MHCII)-bound peptides (epitopes) displayed at the surfaces of dendritic cells (DCs) that have trafficked from sites of infection to regional lymph nodes. While most studies concentrate on the primary response, the majority of pathogen exposures in nature are repeat encounters that play out in decidedly different contexts. Indeed, we hypothesize that activation of memory TCD4+, increasingly appreciated as a key aspect of the recall response, is fundamentally distinct. This is attributable in large part to the presence of antigen-specific B cells, which possess unique antigen processing capabilities. Consequently, this drives a significant shift in the TCD4+ specificities that emerge from recall vs. primary responses. Through well-established influenza models that play to the experience of both co-PIs, this hypothesis will be pursued via two tightly linked specific aims. In the first aim the impact of B cells in the secondary response will be assessed by: a) selectively eliminating or turning on MHCII on memory B cells prior to a secondary challenge, and b) restricting flu protein expression to specific cell types by engineering viruses that contain selective miRNA targeting sequences. In the second aim the antigen processing and presenting capabilities of ex vivo flu-specific B cells vs. DCs will be assessed by in vitro TCD4+ activation assays. The prediction is that the observed differences between these antigen presenting cell (APC) types will provide a basis for the TCD4+ specificities that are amplified during the secondary vs. primary responses. This project is expected to set the stage for studies that explore the processing machinery that facilitates B cell-mediated presentation, the role of memory B cells in responses to other pathogens, as well as more applied studies that leverage resulting principles to enhance rational vaccine design.
描述(由申请人提供):幼稚CD 4 + T细胞(TCD 4+)的激活是由树突状细胞(DC)表面展示的MHC II类(MHCII)结合肽(表位)驱动的,这些细胞从感染部位运输到局部淋巴结。虽然大多数研究都集中在初级反应上,但自然界中的大多数病原体暴露都是在完全不同的环境中重复遭遇的。事实上,我们假设,激活的记忆TCD4+,越来越多的赞赏作为一个关键方面的回忆反应,是根本不同的。这在很大程度上归因于抗原特异性B细胞的存在,它们具有独特的抗原加工能力。因此,这驱动了回忆与主要反应中出现的TCD4+特异性的重大转变。通过完善的流感模型,发挥两个共同PI的经验,这一假设将通过两个紧密联系的具体目标。在第一个目标中,通过以下方式评估B细胞在二次应答中的影响:a)在二次攻击之前选择性地消除或开启记忆B细胞上的MHCII,和B)通过工程化含有选择性miRNA靶向序列的病毒将流感蛋白表达限制于特定细胞类型。在第二个目的中,将通过体外T ⑶ 4+活化测定来评估离体流感特异性B细胞相对于DC的抗原加工和呈递能力。预测是,这些抗原呈递细胞(APC)类型之间观察到的差异将为在二次应答与一次应答期间扩增的TCD4+特异性提供基础。该项目预计将为探索促进B细胞介导的呈递的加工机制、记忆B细胞在对其他病原体的反应中的作用以及利用所得原理来增强合理疫苗设计的更多应用研究奠定基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Laurence Crane Eisenlohr其他文献

Laurence Crane Eisenlohr的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Laurence Crane Eisenlohr', 18)}}的其他基金

Targeting of RAG-dependent and -independent innate immune responses by the Ectromelia C15 protein
Ectromelia C15 蛋白靶向 RAG 依赖性和非依赖性先天免疫反应
  • 批准号:
    10364738
  • 财政年份:
    2021
  • 资助金额:
    $ 29.4万
  • 项目类别:
Targeting of RAG-dependent and -independent innate immune responses by the Ectromelia C15 protein
Ectromelia C15 蛋白靶向 RAG 依赖性和非依赖性先天免疫反应
  • 批准号:
    10205831
  • 财政年份:
    2021
  • 资助金额:
    $ 29.4万
  • 项目类别:
Delineating the non-conventional MHC class I and class II peptidome of influenza
描述流感的非传统 MHC I 类和 II 类肽组
  • 批准号:
    10041955
  • 财政年份:
    2020
  • 资助金额:
    $ 29.4万
  • 项目类别:
Delineating the non-conventional MHC class I and class II peptidome of influenza
描述流感的非传统 MHC I 类和 II 类肽组
  • 批准号:
    10171775
  • 财政年份:
    2020
  • 资助金额:
    $ 29.4万
  • 项目类别:
Defining the MHC-II processing and presentation landscape of HIV-1
定义 HIV-1 的 MHC-II 处理和表达景观
  • 批准号:
    9762836
  • 财政年份:
    2018
  • 资助金额:
    $ 29.4万
  • 项目类别:
MHCII Cross-presentation as a Driver of CD4+ T Cell Responses to Poxviruses
MHCII 交叉呈递作为 CD4 T 细胞对痘病毒反应的驱动因素
  • 批准号:
    9198974
  • 财政年份:
    2015
  • 资助金额:
    $ 29.4万
  • 项目类别:
MHCII Cross-presentation as a Driver of CD4+ T Cell Responses to Poxviruses
MHCII 交叉呈递作为 CD4 T 细胞对痘病毒反应的驱动因素
  • 批准号:
    9108850
  • 财政年份:
    2015
  • 资助金额:
    $ 29.4万
  • 项目类别:
Alternative MHCII Processing of Influenza Virus Proteins
流感病毒蛋白的替代 MHCII 加工
  • 批准号:
    8764161
  • 财政年份:
    2014
  • 资助金额:
    $ 29.4万
  • 项目类别:
Alternative MHCII Processing of Influenza Virus Proteins
流感病毒蛋白的替代 MHCII 加工
  • 批准号:
    9061590
  • 财政年份:
    2014
  • 资助金额:
    $ 29.4万
  • 项目类别:
Alternative MHCII Processing of Influenza Virus Proteins
流感病毒蛋白的替代 MHCII 加工
  • 批准号:
    9280869
  • 财政年份:
    2014
  • 资助金额:
    $ 29.4万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 29.4万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 29.4万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 29.4万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 29.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 29.4万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 29.4万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 29.4万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 29.4万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 29.4万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 29.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了